Impact of Type 2 Diabetes and Postmenopausal Hormone Therapy on Incidence of Cognitive Impairment in Older Women.

Citation data:

Diabetes care, ISSN: 1935-5548, Vol: 38, Issue: 12, Page: 2316-24

Publication Year:
2015
Usage 302
Abstract Views 241
Link-outs 23
Clicks 21
Full Text Views 17
Captures 54
Exports-Saves 53
Readers 1
Mentions 7
News Mentions 7
Social Media 4
Tweets 4
Citations 13
Citation Indexes 13
Repository URL:
https://escholarship.umassmed.edu/prc_pubs/58
PMID:
26486190
DOI:
10.2337/dc15-1385
PMCID:
PMC4657616
ClinicalTrials.gov Identifier:
NCT00000611
Author(s):
Espeland, Mark A.; Brinton, Roberta Diaz.; Hugenschmidt, Christina; Manson, JoAnn E.; Craft, Suzanne; Yaffe, Kristine; Weitlauf, Julie; Vaughan, Leslie; Johnson, Karen C.; Padula, Claudia B.; Jackson, Rebecca D.; Resnick, Susan M.; WHIMS Study Group; Ockene, Judith K. Show More Hide
Publisher(s):
American Diabetes Association
Tags:
Medicine; Nursing; Endocrinology, Diabetes, and Metabolism; Obstetrics and Gynecology; Psychiatry and Psychology; Women's Health
Most Recent Tweet View All Tweets
Most Recent News Mention
article description
In older women, higher levels of estrogen may exacerbate the increased risk for cognitive impairment conveyed by diabetes. We examined whether the effect of postmenopausal hormone therapy (HT) on cognitive impairment incidence differs depending on type 2 diabetes.